MCE - Delayed Quote • EUR
At close: June 11 at 5:35 PM GMT+2
Line
Candle
Baseline
Mountain
Bar
Loading Chart for GRF.MC
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous Close
9.12 - Open
9.17 - Bid 9.06 x --
- Ask 9.07 x --
- Day's Range
9.02 - 9.19 - 52 Week Range
6.36 - 15.92 - Volume
1,362,894 - Avg. Volume
3,222,312 - Market Cap (intraday)
5.47B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
100.20 - EPS (TTM)
0.09 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 3, 2021
- 1y Target Est
18.71
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
23,000
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
More about Grifols, S.A.
Recent News: GRF.MC
All SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
Performance Overview: GRF.MC
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is IBEX 35...
YTD Return
GRF.MC
41.65%
IBEX 35...
10.63%
1-Year Return
GRF.MC
20.83%
IBEX 35...
20.04%
3-Year Return
GRF.MC
59.69%
IBEX 35...
22.35%
5-Year Return
GRF.MC
61.12%
IBEX 35...
20.24%
Compare To: GRF.MC
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
9.02
-1.10%
Mkt Cap EUR 5.47B
Industry Drug Manufacturers—General
27.08
-1.44%
Mkt Cap EUR 26.604B
Industry Drug Manufacturers—General
89.89
-0.42%
Mkt Cap EUR 112.336B
Industry Drug Manufacturers—General
147.50
-1.11%
Mkt Cap EUR 228.663B
Industry Drug Manufacturers—General
303.00
0.00%
Mkt Cap 214.15B
Industry Drug Manufacturers—General
241.60
+0.79%
Mkt Cap CHF 195.377B
Industry Drug Manufacturers—General
94.08
-0.23%
Mkt Cap CHF 191.962B
Industry Drug Manufacturers—General
145.90
-0.14%
Mkt Cap -
Industry Drug Manufacturers—General
18.98
-0.50%
Mkt Cap EUR 77.676B
Industry Drug Manufacturers—General
148.75
-0.10%
Mkt Cap EUR -
Industry Drug Manufacturers—General
27.13
-1.18%
Mkt Cap EUR -
Industry Drug Manufacturers—General
Statistics: GRF.MC
Valuation Measures
As of 6/10/2024
Market Cap
5.53B
Enterprise Value
15.00B
Trailing P/E
101.31
Forward P/E
18.05
PEG Ratio (5yr expected)
0.32
Price/Sales (ttm)
0.94
Price/Book (mrq)
1.06
Enterprise Value/Revenue
2.28
Enterprise Value/EBITDA
12.69
Financial Highlights
Profitability and Income Statement
Profit Margin
2.84%
Return on Assets (ttm)
2.30%
Return on Equity (ttm)
3.48%
Revenue (ttm)
6.66B
Net Income Avi to Common (ttm)
189M
Diluted EPS (ttm)
0.09
Balance Sheet and Cash Flow
Total Cash (mrq)
608.92M
Total Debt/Equity (mrq)
140.31%
Levered Free Cash Flow (ttm)
-1.51B
Research Analysis: GRF.MC
Company Insights: GRF.MC
Research Reports: GRF.MC
People Also Watch
IAG.MC International Consolidated Airlines Group S.A.
1.9840
-0.50%
ACS.MC ACS, Actividades de Construcción y Servicios, S.A.
39.90
-1.77%
ACX.MC Acerinox, S.A.
9.89
-0.15%
CLNX.MC Cellnex Telecom, S.A.
32.54
-3.10%
FER.MC Ferrovial SE
35.60
-1.28%
SAB.MC Banco de Sabadell, S.A.
1.8655
-1.82%
ENG.MC Enagás, S.A.
14.30
-2.39%
ITX.MC Industria de Diseño Textil, S.A.
45.47
-0.53%
CABK.MC CaixaBank, S.A.
5.10
-3.15%
MAP.MC Mapfre, S.A.
2.1500
-2.45%
IDR.MC Indra Sistemas, S.A.
20.94
-2.70%
ELE.MC Endesa, S.A.
18.26
-1.56%
REP.MC Repsol, S.A.
14.46
-1.67%
ANA.MC Acciona, S.A.
117.00
-1.10%
MTS.MC ArcelorMittal S.A.
22.68
-2.66%
BKT.MC Bankinter, S.A.
7.78
-2.31%